Fundraising Fox
/Companies
Sign in

BioPhoundry

Chapel Hill, US · Founded 2024 · Delaware corporation · 1 known investors

Find your way into BioPhoundry

Sign up to see every warm intro you have to BioPhoundry

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the BioPhoundry team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Biophoundry develops phage-based technologies for therapeutics, diagnostics, and bio-molecular engineering, including its Phax platform aimed at making phage therapy faster and more affordable. The company focuses on precision antibiotics to address antimicrobial resistance, combining synthetic biology, robotics, and data science.

AI & Machine LearningBiotechHealthtech

Founders & leadership

BioPhoundry was founded in 2024 by Rani Brooks.

RB
Rani BrooksCEO & Co-Founder
SB
Sahan B.W. LiyanagederaNamed on SEC filing

Board

LM
Louis MarlowBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 round · 2024

▶$1.1MraisedJan 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Louis MarlowDirector
  • Sahan B.W. LiyanagederaExecutive Officer, Director
  • Rani T. BrooksExecutive Officer, Director
Offering amount
$1.2M
Amount sold
$1.1M
First sale
Dec 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does BioPhoundry do?
Biophoundry develops phage-based technologies for therapeutics, diagnostics, and bio-molecular engineering, including its Phax platform aimed at making phage therapy faster and more affordable. The company focuses on precision antibiotics to address antimicrobial resistance, combining synthetic biology, robotics, and data science.
Who founded BioPhoundry?
BioPhoundry was founded by Rani Brooks in 2024.
Who are BioPhoundry's investors?
BioPhoundry's investors include Creator Fund.
How much funding has BioPhoundry raised?
BioPhoundry has disclosed $1.1M raised across 1 round.
Where is BioPhoundry headquartered?
BioPhoundry is headquartered in Chapel Hill, US.